Advertisement
Australia markets open in 1 hour 15 minutes
  • ALL ORDS

    8,065.50
    +113.20 (+1.42%)
     
  • AUD/USD

    0.6594
    -0.0032 (-0.48%)
     
  • ASX 200

    7,793.30
    +110.90 (+1.44%)
     
  • OIL

    78.39
    +0.01 (+0.01%)
     
  • GOLD

    2,323.80
    -0.40 (-0.02%)
     
  • Bitcoin AUD

    95,602.25
    -708.55 (-0.74%)
     
  • CMC Crypto 200

    1,305.60
    -59.53 (-4.36%)
     

Regis Healthcare Limited (ASX:REG) Insiders Increased Their Holdings

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So we'll take a look at whether insiders have been buying or selling shares in Regis Healthcare Limited (ASX:REG).

What Is Insider Buying?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, most countries require that the company discloses such transactions to the market.

Insider transactions are not the most important thing when it comes to long-term investing. But it is perfectly logical to keep tabs on what insiders are doing. For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.

ADVERTISEMENT

View our latest analysis for Regis Healthcare

The Last 12 Months Of Insider Transactions At Regis Healthcare

In the last twelve months, the biggest single purchase by an insider was when Independent Chairman Graham Hodges bought AU$94k worth of shares at a price of AU$3.13 per share. That implies that an insider found the current price of AU$3.35 per share to be enticing. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Regis Healthcare insiders decided to buy shares at close to current prices.

While Regis Healthcare insiders bought shares last year, they didn't sell. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

ASX:REG Recent Insider Trading, October 14th 2019
ASX:REG Recent Insider Trading, October 14th 2019

Regis Healthcare is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Does Regis Healthcare Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It's great to see that Regis Healthcare insiders own 56% of the company, worth about AU$564m. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

What Might The Insider Transactions At Regis Healthcare Tell Us?

The fact that there have been no Regis Healthcare insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. It would be great to see more insider buying, but overall it seems like Regis Healthcare insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Regis Healthcare.

Of course Regis Healthcare may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.